ATE383429T1 - Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung - Google Patents

Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung

Info

Publication number
ATE383429T1
ATE383429T1 AT97940030T AT97940030T ATE383429T1 AT E383429 T1 ATE383429 T1 AT E383429T1 AT 97940030 T AT97940030 T AT 97940030T AT 97940030 T AT97940030 T AT 97940030T AT E383429 T1 ATE383429 T1 AT E383429T1
Authority
AT
Austria
Prior art keywords
diagnostic
binding domain
therapeutic use
fusion polypeptides
polypeptides containing
Prior art date
Application number
AT97940030T
Other languages
English (en)
Inventor
Mary Digan
Philip Lake
Hermann Gram
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE383429T1 publication Critical patent/ATE383429T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97940030T 1996-07-26 1997-07-25 Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung ATE383429T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69021696A 1996-07-26 1996-07-26

Publications (1)

Publication Number Publication Date
ATE383429T1 true ATE383429T1 (de) 2008-01-15

Family

ID=24771594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97940030T ATE383429T1 (de) 1996-07-26 1997-07-25 Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung

Country Status (27)

Country Link
EP (1) EP0917581B1 (de)
JP (1) JP3681402B2 (de)
KR (1) KR100502879B1 (de)
CN (1) CN1146664C (de)
AR (1) AR008077A1 (de)
AT (1) ATE383429T1 (de)
AU (1) AU722069B2 (de)
BR (1) BR9710605A (de)
CA (1) CA2261562C (de)
CO (1) CO4650184A1 (de)
CZ (1) CZ297634B6 (de)
DE (1) DE69738452T2 (de)
ES (1) ES2300114T3 (de)
ID (1) ID19420A (de)
IL (2) IL128094A0 (de)
MY (1) MY120425A (de)
NO (1) NO323611B1 (de)
NZ (1) NZ333908A (de)
PE (1) PE99498A1 (de)
PL (1) PL189415B1 (de)
PT (1) PT917581E (de)
RU (1) RU2209211C2 (de)
SK (1) SK7799A3 (de)
TR (1) TR199900155T2 (de)
TW (1) TW565571B (de)
WO (1) WO1998004718A1 (de)
ZA (1) ZA976666B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1056471A4 (de) * 1998-01-29 2001-05-30 Tanox Inc BEHANDLUNG ATOPISCHER DERMATITIS MIT IgE ANTAGONISTEN
CA2330527A1 (en) * 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
EP1208194A2 (de) * 1999-08-09 2002-05-29 Genaissance Pharmaceuticals, Inc. Isogene arzneimittel-ziele: polymorphismen des gens der immunglobulin e rezeptor i alpha untereinheit
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
DE10026998A1 (de) * 2000-05-31 2001-12-13 Fresenius Kabi De Gmbh Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
DK2401383T3 (da) 2009-02-27 2013-12-16 Novartis Ag Fremgangsmåder til udvælgelse af eukaryote celler, som udtrykker et heterologt protein
WO2012169735A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물
RU2506271C2 (ru) * 2011-06-22 2014-02-10 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД А2, СЕЛЕКТИВНО СВЯЗЫВАЮЩИЙ HSA, РЕКОМБИНАНТНАЯ ДНК pa2, КОДИРУЮЩАЯ HSA-СВЯЗЫВАЮЩУЮ ЧАСТЬ ПОЛИПЕПТИДА A2, ЕГО ПРОДУЦЕНТ - РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15-A2, СОДЕРЖАЩИЙ РЕКОМБИНАНТНУЮ ПЛАЗМИДНУЮ ДНК pQE 32-pa2, ОБЕСПЕЧИВАЮЩУЮ ПОЛУЧЕНИЕ ПОЛИПЕПТИДА A2 И ПРИМЕНЕНИЕ ПОЛИПЕПТИДА А2 ДЛЯ ДИАГНОСТИКИ МИКРОАЛЬБУМИНУРИИ И ВЫДЕЛЕНИЯ HSA ИЗ СЫВОРОТКИ КРОВИ
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
JP2018515073A (ja) * 2015-05-04 2018-06-14 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Ｆｃ融合タンパク質のトランスジェニック産生
EP3192806A1 (de) 2016-01-13 2017-07-19 Affiris AG Alpha-kette des hochaffinen ige-rezeptors (fceria)
JP7127859B2 (ja) * 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
BR112022000246A2 (pt) * 2019-07-08 2022-02-22 Gi Innovation Inc Dímero polipeptídico com elevado teor de ácido siálico, compreendendo o domínio extracelular da subunidade alfa do receptor fc de ige e composição farmacêutica compreendendo o mesmo
CN114302891A (zh) * 2019-07-08 2022-04-08 普罗根有限公司 新的il-10变体蛋白及其用途
CN111773392B (zh) * 2020-05-25 2023-04-07 河南省生物工程技术研究中心 一种人血白蛋白/寡核苷酸纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
CA2059842A1 (en) * 1991-02-11 1992-08-12 Richard A. Chizzonite Ige-receptor-antibodies

Also Published As

Publication number Publication date
JP3681402B2 (ja) 2005-08-10
CZ24699A3 (cs) 1999-04-14
IL128094A0 (en) 1999-11-30
CA2261562C (en) 2011-04-05
AU722069B2 (en) 2000-07-20
PL189415B1 (pl) 2005-08-31
ES2300114T3 (es) 2008-06-01
CN1229439A (zh) 1999-09-22
IL128094A (en) 2006-08-20
NO990328L (no) 1999-02-19
AU4202597A (en) 1998-02-20
EP0917581B1 (de) 2008-01-09
CA2261562A1 (en) 1998-02-05
EP0917581A1 (de) 1999-05-26
DE69738452D1 (de) 2008-02-21
WO1998004718A1 (en) 1998-02-05
ID19420A (id) 1998-07-09
CO4650184A1 (es) 1998-09-03
KR100502879B1 (ko) 2005-07-25
SK7799A3 (en) 1999-07-12
JP2000516089A (ja) 2000-12-05
NO990328D0 (no) 1999-01-25
MY120425A (en) 2005-10-31
DE69738452T2 (de) 2008-12-24
HK1020352A1 (en) 2000-04-14
KR20000029563A (ko) 2000-05-25
NO323611B1 (no) 2007-06-18
TW565571B (en) 2003-12-11
PE99498A1 (es) 1999-01-21
ZA976666B (en) 1999-01-25
CN1146664C (zh) 2004-04-21
TR199900155T2 (xx) 2000-08-21
RU2209211C2 (ru) 2003-07-27
AR008077A1 (es) 1999-12-09
PT917581E (pt) 2008-04-11
NZ333908A (en) 1999-10-28
BR9710605A (pt) 1999-08-17
CZ297634B6 (cs) 2007-02-21
PL331356A1 (en) 1999-07-05

Similar Documents

Publication Publication Date Title
ATE383429T1 (de) Fusionspolypeptide die eine ige-bindungsdomäne und eine hsa-komponente enthalten und deren diagnostische und therapeutische verwendung
DE69706948D1 (de) Weichlotwerkstoff und dessen Verwendung in ein elektronisches Bauteil
DE69729149D1 (de) Prozesskassette und Bilderzeugungsgerät mit herausnehmbarer Prozesskassette
NO963371D0 (no) Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
DE69634122D1 (de) Heterocyclische amidverbindungen und deren medizinische verwendung
EP0790826A4 (de) Dyhydropyrimidine und deren verwendungen
DE69031783D1 (de) Bildaufzeichnungsmaterial und Bildaufzeichnungsverfahren damit
DE69526969D1 (de) Thermoplastische harzzusammensetzung und seine verwendung
DE59506234D1 (de) Pigmentzubereitung und deren Verwendung
CY2007003I1 (el) Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινη
DE69632678D1 (de) Harzzusammensetzung und deren verwendung
DE69718839D1 (de) Informationsaufzeichnungsverfahren und Vorrichtung mit Zusatzaufzeichnungsfunktion
DE69631240D1 (de) Schaltvorrichtung und deren verwendung
DE69712851D1 (de) Applikator für ein streichfähiges Produkt sowie eine Applikationseinheit mit solch einem Applikator
DE69817432D1 (de) Cycloolefinpolymere und deren Verwendung
DE59504919D1 (de) Verfahren zur herstellung von ammonium-2-hydroxy-4-(methylthio)-butyrat und dieses enthaltende mischungen in flüssiger form und deren verwendung
DE69713512D1 (de) Substituierte phtalocyanine und deren verwendung
DE69431350D1 (de) Vergiessbares canola-öl und dessen verwendung in nahrungsmitteln
DE69519821D1 (de) Pulverförmiges Material zur Verwendung beim Wiederstandsschweissen von Aluminiumgegenständen und Wiederstandsschweissen von Aluminiumgegenständen
DE69835007D1 (de) Entkoffeinierte mate-extrakte und deren verwendung
DE69624048D1 (de) Elektrisch geheizter Wabenkörper und einen solchen Wabenkörper einschliessende Einheit
DE69411942D1 (de) Mehrschichtenmaterial und eine dieses material enthaltende anordnung
ATE98246T1 (de) Substituierte pyrrolizinverbindungen und deren anwendung in der pharmazie.
DE69631632D1 (de) Schaltvorrichtung und deren verwendung
DE69834174D1 (de) Epidermales protein aus der hornhautschicht und seine verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0917581

Country of ref document: EP